Damage To the Peripheral Nervous System in COVID-19 Infection
DOI:
https://doi.org/10.61788/njn.v2i24.08Keywords:
COVID-19, neuropathy, Guillain-Barre syndrome, anosmia, dysgeusia, antibodies to gangliosidesAbstract
The article provides information about damage to the peripheral nervous system during COVID-19 infection and clarifies the possible mechanisms of development. Also in modern medical literature, a large amount of data on neurological pathologies associated with COVID-19 - damage to the central and peripheral nervous system - has been reviewed and epidemiological indicators of these injuries have been analyzed. The role of immune disorders in the occurrence and further development of damage to the peripheral nervous system was assessed. Guillain-Barre syndrome (GBS), one of the rare neurological pathologies that develops due to COVID-19, is described. Literary data were analyzed to determine the clinical course of GBS and elucidate its probable autoimmune pathogenesis. A clinical observation of the development of GBS against the background of typical manifestations of COVID-19 in a 56-year-old male patient is presented. The interval from the first manifestations of COVID-19 to the manifestation of GBS was 13 days. The GBS that developed was severe, required invasive ventilation, and developed acute kidney injury. It is suggested that the information presented about the pathogenetic mechanism, clinical manifestations, diagnosis and treatment of GBS in patients may stimulate research towards bringing greater clarity to these issues.
References
Bello-Chavolla O., Bahena-López J., Antonio-Villa N. et al. Predicting Mortality Due to SARS-CoV-2: A Mechanistic Score Relating Obesity and Diabetes to COVID-19 Outcomes in Mexico // J Clin Endocrinol Metab. 2020;105(8): dgaa346. DOI: 10.1210/clinem/dgaa346.
Гусев Е.И., Мартынов М.Ю., Бойко А.Н. и др. Новая коронавирусная инфекция (COVID-19) и поражение нервной системы: механизмы неврологических расстройств, клинические проявления, организация неврологической помощи // Журнал неврологии и психиатрии им. С.С. Корсакова. 2020; 120(6):7-16. [Gusev E.I., Martynov M. Yu., Boyko A.N. et al. Novel coronavirus infection (COVID-19) and nervous system involvement: pathogenesis, clinical manifestations, organization of neurological care // S.S.Korsakov Journal of Neurology and Psychiatry. 2020;120(6);7-16 (in Russ.)]. DOI: 10.17116/jnevro 20201200617.
Portela-Sánchez S., Sánchez-Soblechero A., Otalora P. et al. Neurological complications of COVID-19 in hospitalized patients: The registry of a neurology department in the first wave of the pandemic // Eur J Neurol. 2021, Jan 21. DOI: 10.1111/ene.14748.
Mao L., Jin H., Wang M. et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China // JAMA Neurol. 2020;77(6):683-690. DOI: 10.1001/ jamaneurol. 2020.1127.
Menni C., Valdes A.M., Freidin M.B. et al. Real-time tracking of self-reported symptoms to predict potential COVID-19 // Nat Med. 2020;26(7):1037-1040. DOI: 10.1038/s41591-020-0916-2.
Lechien J.R., Cabaraux P., Chiesa-Estomba C. et al. Psychophysical olfactory tests and detection of COVID-19 in patients with sudden onset olfactory dysfunction: A prospective study // Ear Nose Throat J. 2020;99(9):579-583. DOI: 10.1177/0145561320929169.
Zahra S., Iddawela S., Pillai K. et al. Can symptoms of anosmia and dysgeusia be diagnostic for COVID-19? // Brain Behav. 2020;10(11): e01839. DOI: 10.1002/brb3.1839.
Uncini A., Vallat J.-M., Jacobs B.C. Guillain-Barré syndrome in SARS-CoV-2 infection: an instant systematic review of the first six months of pandemic // J Neurol Neurosurg Psychiatry. 2020;91 (10): 1105-1110. DOI: 10.1136/jnnp-2020-324491.
Abu-Rumeileh S., Abdelhak A., Foschi M. Guillain-Barré syndrome spectrum associated with COVID-19: an uptodate systematic review of 73 cases // J Neurol. 2020;1-38. DOI: 10.1007/ s00415-020-10124-x.
Fragiel M., Miró Ò., Llorens P. et al. Incidence, clinical, risk factors and outcomes of Guillain-Barré in Covid-19 // Ann Neurol. 2020. DOI: 10.1002/ana.25987. Online ahead of print.
Hasan I., Saif-Ur-Rahman K.M., Hayat S. et al. Guillain-Barré syndrome associated with SARS-CoV-2 infection: a systematic review and individual participant data metaanalysis // J Peripher Nerv Syst. 2020;25:335-343. DOI: 10.1111/jns.12419.
Horby P., Landary M. Recovery trial, 2020. (Electronic resource.) URL: https://www. recoverytrial. net (access date: 02.06.2020).
Falcone M., Rong A., Salazar H. et al. Acute abducens nerve palsy in a patient with the novel coronavirus disease (COVID-19). Acute abducens nerve palsy in a patient with the novel coronavirus disease (COVID-19) // JAAPOS. 2020;24(4):216-217. DOI: 10.1016/j.jaapos. 2020.06.001.
Raharimanantsoa O., Razakarivony F., Andriamiadanalisoa A. et al. Multinévrite oculaire dans le cadre d’une infection COVID-19 Multiple infectious cranial nerve palsies in COVID-19 // J Fr Ophtalmol. 2020;43(10): e351-e353. DOI: 10.1016/j.jfo.2020.08.001.
Raahimi M., Kane A., Moore C., Alareed A. Late onset of Guillain-Barré syndrome following SARS-CoV-2 infection: part of ‘long COVID-19 syndrome’? // BMJ Case Rep. 2021;14: e240178. DOI: 10.1136/bcr-2020-240178.
Malek E., Salameh J. Guillain-Barre Syndrome // Semin Neurol. 2019;39:589-595. DOI: 10.1055/ s-0039-1693005.
Ellul M., Benjamin L., Singh B. et al. Neurological associations of COVID19 // Lancet Neurol. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3589350. DOI: 10.1016/S1474-4422 (20) 30221-0.
Willison H.J., Jacobs B.C., van Doorn P.A. Guillain-Barré syndrome // Lancet. 2016;388 (10045): 717-727. DOI: 10.1016/S0140-6736 (16) 00339-1.
Caress J.B., Castoro R.J., Simmons Z. et al. COVID-19-Associated Guillain-Barre Syndrome: The Early Pandemic Experience // Muscle Nerve. 2020;62(4):485-491. DOI: 10.1002/mus.27024.
Rudant J., Dupont A., Mikaeloff Y. et al. Surgery and risk of Guillain-Barré syndrome: A French nationwide epidemiologic study // Neurology. 2018;91(13):e1220-e1227. DOI: 10.1212/ WNL. 000000000000 6246.
Rodríguez Y., Novelli L., Rojas M. et al. Autoinflammatory and autoimmune conditions at the crossroad of COVID-19 // J Autoimmun. 2020; 114:102506. DOI: 10.1016/j.jaut.2020.102506.
Vlachoyiannopoulos P.G., Magira E., Alexopoulos H. et al. Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19 // Ann Rheum Dis. 2020 Jun 24. DOI: 10.1136/annrheumdis-2020-218009.
Kaida K, Ariga T, Yu RK. Antiganglioside antibodies and their pathophysiological effects on Guillain-Barré syndrome and related disorders - a review // Glycobiology. 2009 Jul;19(7):676-92.
Бондарь С.А., Маслянский А.Л., Смирнова А.Ю., Новожилова М.А., Симаков К.В., Янишевский С.Н., Конради А.О. Синдром Гийена - Барре и COVID-19: клинические наблюдения // Русский медицинский журнал. 2021;5:60-64. [Bondar S.A., Maslyansky A.L., Smirnova A.Yu., Novozhilova M.A., Simakov K.V., Yanishevsky S.N., Konradi A.O. Guillain-Barré syndrome and COVID-19: clinical observations // Russian medical journal. 2021;5:60-64. (in Russ.)]
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 National Association of Neurologists
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
